LATEST TRIALS

  • Renal Cancer
    A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
  • Solide Tumores
    A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site...
  • Melanoma
    A randomized, douple-blind, phase 2/3 study of relatlimab combined with nivolumab versus nivolumab in participants with previously untreated metastatic or unresectable melanoma

NORDIC COOPERATION

Norway Norway Sweden Finland Finland Finland Aarhus Herlev Copenhagen Copenhagen Lund